ONLINE APPENDIX

TABLE I: Clinical data of Patients with Macular Hole

| Age/SEX | Past History | Treatment for Systemic Disorder | Other Ocular Disorder | Duration of Vision Loss | Eye Affected | Macular Hole Grade | Treatment | Baseline Investigations |
|---------|--------------|---------------------------------|-----------------------|-------------------------|--------------|-------------------|-----------|------------------------|
| 61/F    | GoPD Deficiency T. Olvo T. Nayapred T. Oplex | NIL | 1 Month | OD | FTMH | NIL | RBS- 103 BU- 32 SCR- 1.07 |
| 55/M    | NIL | NIL | 2 Years | OD | FTMH | NIL | RBS- 133 |
| 31/M    | HT | NIL | 3 Months | OD | FTMH | NIL | RBS- 100 |
| 54/F    | Raised BS levels T. Glyciphage 500mg T. Losar 50 | NIL | 6 months | OU | FTMH | NIL | RBS- 233 |
| 63/M    | NIL | NIL | 6 months | OS | FTMH | NIL | RBS- 115 BU- 15 SCR- 0.9 |
| 65/F    | Trigeminal neuralgia T. tegretal CR T. Baclofen | NIL | 4 months | OS | FTMH | NIL | RBS- 138 BU- 23 SCR- 0.8 |
| 67/M    | | | 1 month | OD | | | |
| 57/M    | NIL | NIL | 2 years | OU | OD= FTMH OS= Lamellar MH | NIL | RBS 108 |

FTMH, full thickness macular hole; PVD, posterior vitreous detachment; CNVM, choroidal neovascular membrane; ERM, epiretinal membrane; RBS, random blood sugar; SCR, serum creatinine; BU, blood urea.
### TABLE II: Clinical Data of patients with PDR

| Age/ Sex | Past Treatment History | Duration of Diabetes (yrs) | Type | DR Quadrant | Vit Haem | Retinal Detachment | Other features | Eye Operated | Treatment | Baseline Investigations | Associated Disorder |
|----------|------------------------|-----------------------------|------|-------------|---------|--------------------|----------------|--------------|-----------|------------------------|-------------------|
| 43/ F    | None                   | 16                          | 1    | 4           | +       | TRD                | OU=FVP         | OU           | T losar, T Femolid,   | RBS-322, BU-22, SCR-0.8 | Hypercholesterolemia |
| 61/ F    | None                   | 29                          | 1    | 4           | -       | CRD                | OD= 360° NVI FVP | OD           | T Atenolol, T Lipitor, T Pioglitazone | RBS 300, BU-69, SCR-2.5 | HT, Hypercholesterolemia, CKD Stage IV |
| 54/ M    | Laser, Anti VEGF       | 3                           | 1    | 4           | +       | None               | OU=PVD         | OU           | T Glumet,             | RBS-251, SCR -1.5 BU-39 | HT |
| 52/ M    | Laser                  | 26                          | 1    | 4           | +       | TRD+ VMT           | OS= 360° NVI OD=ERM | OS           | T Glucoret Forte, Acarbose | RBS-287, BU-18 S SCR-1.00 | None |
| 47/ M    | None                   | 15                          | 1    | 4           | OD +    | TRD                | OD=FVP         | OU           | T Glycidem, T Isinexex, T Ethanbutol | RBS-251, SCR-1.1. BU 26 | HT, DN |
| 53/ M    | Laser                  | 20                          | 1    | 4           | OS +    | OS=TRD             | OU= NVE,NVD, FVP | OU           | T Nalop, T Atorva, T Glycalazide, T Metformin T Asprin | RBS-241. BU 35, SCR-1.1 | Hypercholesterolemia |
| 46/ F    | Laser                  | 20                          | 1    | 4           | OD +    | CRD                | OS=FVP         | OD           | T Reclide, T Aztor 10mg. | RBS-231, BU -23, | None |

©2010 American Diabetes Association. Published online at [http://care.diabetesjournals.org/cgi/content/full/dc10-0132/DC1](http://care.diabetesjournals.org/cgi/content/full/dc10-0132/DC1)
| ID  | Age | Gender | Eyes  | Duration | Snellen | Ocular Findings | Medical History | Laboratory Values | Treatments                                      |
|-----|-----|--------|-------|----------|---------|-----------------|----------------|------------------|-----------------------------------------------|
| 68M | 68  | M      | 1     | 4 months | +       | OD=CRD          | T Gemet, T Metpure XI, T Atorva, T Olmesar H | RBS-159, BU-38, SCR-1.1 | HT                                           |
| 49M | 49  | M      | 2     | 1 month  | OD=±    | OS=TRD          | T Eslo 5, T Glimi H2, T lipicure | RBS-231, BU-33, SCR-1 | HT, DN                                       |
| 54M | 54  | M      | 3     | 2 months | OS=+    | OD=FVP, NVE     | T Glyclazide, Bisoprolol, T Orlibose, T Mini Press, T Telvas, T Amlodipine | RBS 152, BU 39, SCR-1.4 | None                                         |
| 54F | 54  | F      | 4     | 2 months | OS=+    | OD=NVD          | Inj Mixtard 12-0-12, T Atorva, T Rapace, T Glynace MF, T Stamlo beta | RBS 287, FBS-210, BU-40, SCR-1.2 | HTN, DN, HYPOTHYROIDISM                      |
| 48F | 48  | F      | 5     | 2 months | OS=+    | None            | T Atocar, T Pyoglit, T Dyotor, T Glynipide, T Amtas | BU-51, Scr-1.5, RBS-160 | CRF cardiomyopathy                           |
| 53M | 53  | M      | 6     | 4 months | OS=+    | OD=CSME         | T Glucored, T Envas | RBS-337, BU-31, SCR-1.1 | None                                         |
HT, Hypertension; CKD, chronic kidney disease; CRF, chronic renal failure; VEGF: vascular endothelial growth factor; CSME, clinically significant macular edema; TRD, tractional retinal detachment; CRD, combined retinal detachment; NVE, neovascularisation elsewhere; NVI, neovascularization iris; NVD, neovascularization disc; FVP, fibrovascular proliferation; DR, diabetic retinopathy; DN, diabetic nephropathy; VMT, vitreomacular traction; RBS, random blood sugar; SCR, serum creatinine; BU, blood urea.
